

**NZX/ASX Announcement**

27 February 2025

## **TruScreen Signs MOU with Hangzhou Dalton Bioscience to Expand its HPV Product Offerings**

- **TruScreen Group Limited has signed a non-binding Memorandum of Understanding (“MOU”) with Hangzhou Dalton Bioscience Limited (“DaltonBio”), a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening.**
- **The MOU provides a framework for collaboration to distribute, and marketing of complementary HPV related In Vitro Diagnostics (“IVD”) products through the selected TruScreen global distribution network, under the TruScreen brand.**
- **The MOU supports TruScreen’s strategy to expand its HPV related product portfolio that strengthens its global position in the women’s health sector.**

**TruScreen Group Limited (NZX/ASX: TRU), (“TruScreen” or “the Company”),** a global leader in AI-enabled cervical cancer screening, is pleased to announce that it has signed a non-binding MOU with DaltonBio, a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening, to expand global commercial opportunities for a suite of DaltonBio’s HPV related IVD products to be marketed under the TruScreen brand.

The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the technology strengths of both companies.

Pursuant to the MOU, TruScreen and DaltonBio will negotiate to formalise a distribution agreement within three months from the date of the MOU. The proposed collaboration consists of two key stages:

1. **Short-Term Collaboration:** TruScreen will conduct due diligence on DaltonBio’s HPV related IVD products, namely HPV DNA tests, and self-sampling tests for marketing through TruScreen’s selected global distribution network.
2. **Medium-to-Long-Term Strategic Alliance:** Subject to a successful stage 1 collaboration, TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada). DaltonBio to explore opportunities to assist TruScreen’s AI enabled real time cervical screening device within its distribution network, notably in its selected distributors in China and South America.

**TruScreen CEO, Marty Dillon** commented: *"This collaboration is a significant step forward in our mission to provide innovative and accessible cervical cancer screening solutions worldwide. Dalton BioSciences HPV screening tests complement TruScreen’s AI enabled real-time cervical screening technology. This will enable TruScreen to offer a range of comprehensive solutions to healthcare providers globally. We are excited about the potential of this partnership and look forward to progressing towards a formal distribution agreement."*

**DaltonBio Founder and President, Dr. Ben Hua** commented: *"Both DaltonBio HPV tests and TruScreen AI enabled screening worked in conjunction with each other as a triage to confirm the positive result of a patient, prior to treatment for HPV cancerous lesions. This collaboration is a natural extension of both companies' technologies to offer best available solutions to healthcare clinicians globally. Our cost-effective high-performance HPV DNA tests and other IVD products for women's health are ideally suited for use in many countries where TruScreen has distribution. We look forward to progressing towards a formal distribution agreement for TruScreen."*

TruScreen was advised by the Sydney team of Hong Kong headquartered Innoklyin Capital Limited .

This announcement has been approved by the Board.

**Ends**

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Martin Dillon

Chief Executive Officer

[martindillon@truscreen.com](mailto:martindillon@truscreen.com)

Guy Robertson

Chief Financial Officer

[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)



#### About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000\* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

*\*Based on Single Use Sensor sales.*



### **About DaltonBio:**

DALTON BioSciences ("DALTONbio®") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio® is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its high performance HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: [www.daltonbio.com/](http://www.daltonbio.com/).

Glossary:

**Pap smear** (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

**LBC** (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

**HPV (human papilloma virus) test** is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

**Sensitivity and specificity** mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)